A self-foaming composition is described that includes clobetasol propionate, for a no-rinse topical application and for application to the skin. The composition can include: at least one intermediate composition B including a gas-generating agent; at least one intermediate composition A including an agent for activating the gas-generating agent; and clobetasol propionate being present in at least one of the intermediate compositions A and B. Also described, is a kit or a single container including a plurality of compartments including such a composition.

An antiviral treatment of infections from Coronavirus, in particular COVID-19, is by administration of a modified nucleoside, derived from adenosine, individually or in combination with other therapeutically active substances. In particular, 3′-deoxyadenosine, or cordycepin, is administered for the treatment of a viral syndrome from Coronavirus, in particular COVID-19, in which 3′-deoxyadenosine is administered individually or in combination with at least one inhibitor or antagonist of the adenosine receptors A1 and A3 and possibly agonist of the adenosine receptors A.sub.2a and/or A.sub.2b. The administration of 3′-deoxyadenosine is subsequent or simultaneous to the administration of the inhibitor, preferably inosine, a molecule which expresses both these functions.

The present invention relates to a new fast dissolvable tablet comprising physiologically active ingredients, which dissolves or can be dispersed in water (or water based liquids) fast.

This invention relates generally to compositions useful for the maintenance of calcium homeostasis. In particular, this invention is directed to apoaequorin-containing effervescent compositions useful in preventing and/or alleviating diseases or symptoms associated with calcium imbalance. Certain embodiments of the invention further contain active ingredients including at least one stimulant (e.g., caffeine) and/or vitamin D.

One solid preparation of the present invention mainly includes silicon fine particles, and has a capability of generating hydrogen. In addition, one specific example of the solid preparation mainly includes silicon fine particles having a crystallite diameter principally of 1 nm or more and 100 nm or less, and exhibits a capability of generating hydrogen in an amount of 3 ml/g or more when brought into contact with a water-containing liquid having a pH value of 7 or more. In this solid preparation, hydrogen is generated when the silicon fine particles are brought into contact with a water-containing liquid having a pH value of 7 or more. Therefore, taking advantage of the characteristics of the solid preparation, generation of hydrogen is promoted in, for example, a gastrointestinal tract where the pH value is 7 or more due to secretion of pancreatic fluid after passage through the stomach after oral ingestion.

Effervescent gel EG agent is a new oral formulation platform. It includes a fast-expanding gel agent, a foam-forming agent, an active ingredient, and an auxiliary ingredient. Effervescent gel is mixed with appropriate amount of aqueous agent or aqueous solution, which can swell rapidly (generally less than 30 seconds) and form a uniform multi-bubble hydrogel, which has the characteristics of fast gel formation, convenient preparation, uniform gel, smooth taste and adjustable viscosity, especially for children, the elderly and patients with swallowing reflex dysfunction. Oral effervescent gels are convenient, safe and have excellent taste, and significantly increase the compliance of pediatric patients, and can be used in the fields of pharmaceuticals, food and health products.

Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T.sub.max of meloxicam of 3 hours or less.

A method for managing and/or treating obesity and/or overweight and/or for inducing weight loss. The method includes orally administering to a patient a composition capable of being transformed into a hydrogel foam after its introduction into the patient stomach. The hydrogel foam occupies at least 20% of the volume of the patient stomach.

This document provides methods and materials for treating hypocapnia. For example, methods and materials for delivering CO.sub.2 to a mammal to treat hypocapnia or compensate for a reduced level of CO.sub.2 are provided.

One solid preparation of the present invention mainly includes silicon fine particles, and has a capability of generating hydrogen. In addition, one specific example of the solid preparation mainly includes silicon fine particles having a crystallite diameter principally of 1 nm or more and 100 nm or less, and exhibits a capability of generating hydrogen in an amount of 3 ml/g or more when brought into contact with a water-containing liquid having a pH value of 7 or more. In this solid preparation, hydrogen is generated when the silicon fine particles are brought into contact with a water-containing liquid having a pH value of 7 or more. Therefore, taking advantage of the characteristics of the solid preparation, generation of hydrogen is promoted in, for example, a gastrointestinal tract where the pH value is 7 or more due to secretion of pancreatic fluid after passage through the stomach after oral ingestion.